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Infantile encephalopathies are a group of clinically and biologically heterogeneous disorders for which the genetic basis remains largely
unknown.Here, we report a syndromic neonatal encephalopathy characterized by profound developmental disability, severe hypotonia,
seizures, diminished respiratory drive requiring mechanical ventilation, brain atrophy, dysgenesis of the corpus callosum, cerebellar
vermis hypoplasia, and facial dysmorphism. Biallelic inactivating mutations in TBCK (TBC1-domain-containing kinase) were indepen-
dently identified by whole-exome sequencing as the cause of this condition in four unrelated families. Matching these families was
facilitated by the sharing of phenotypic profiles and WES data in a recently released web-based tool (Geno2MP) that links phenotypic
information to rare variants in families with Mendelian traits. TBCK is a putative GTPase-activating protein (GAP) for small GTPases of
the Rab family and has been shown to control cell growth and proliferation, actin-cytoskeleton dynamics, and mTOR signaling. Two of
the three mutations (c.376C>T [p.Arg126*] and c.1363A>T [p.Lys455*]) are predicted to truncate the protein, and loss of the major
TBCK isoform was confirmed in primary fibroblasts from one affected individual. The third mutation, c.1532G>A (p.Arg511His), alters
a conserved residue within the TBC1 domain. Structural analysis implicated Arg511 as a required residue for Rab-GAP function, and
in silico homology modeling predicted impaired GAP function in the corresponding mutant. These results suggest that loss of Rab-
GAP activity is the underlying mechanism of disease. In contrast to other disorders caused by dysregulated mTOR signaling associated
with focal or global brain overgrowth, impaired TBCK function results in progressive loss of brain volume.Severe infantile encephalopathy is a non-specific clinical
condition that can be caused by hypoxemia, hemorrhage,
toxins (e.g., hyperbilirubinemia or withdrawal from selec-
tive serotonin-reuptake inhibitors or narcotics), and muta-
tions in multiple genes, such as PURA (MIM: 600473),
UNC80 (MIM: 612636), or NALCN (MIM: 611549).1–9
Over the past 5 years, substantial progress has been made
toward defining the genetic basis of infantile encephalop-
athies; however, the genetic cause remains unknown for a
large proportion of affected individuals, and these condi-
tions have few distinguishing clinical features, making it
challenging to stratify affected individuals for gene-discov-
ery efforts. Whole-exome sequencing (WES) of multiple
independent families affected by non-specific infantile
encephalopathies is a powerful way to discover shared
candidate genes among affected individuals, who upon
further clinical evaluation are often found to share pheno-
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syndromic infantile encephalopathy characterized by
severe developmental disability, brain atrophy, early-onset
focal seizures, central respiratory failure, and facial dys-
morphism.WES in four families led to the discovery ofmu-
tations in TBCK, a gene encoding a putative Rab-specific
GTPase-activating protein (GAP), as the underlying molec-
ular cause.
Clinical data and biological samples were obtained from
four unrelated families after written informed consent was
provided, and studies for each family were approved by the
respective institutional review boards of the University of
Washington (Seattle), the Genetics Services Advisory Com-
mittee (New South Wales), the Universita` La Sapienza
(Rome), and the Children’s Hospital of Philadelphia (Phil-
adelphia). A single affected individual with neonatal-
onset encephalopathy, brain atrophy with cerebellar
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Figure 1. Pedigrees and Pictures of Individuals with TBCK-Related Encephalopathy
(A–D) Pedigrees for families A–D (A–D, respectively), in whom loss-of-functionmutations in TBCK segregate with disease. Solid black fill
indicates individuals affected by TBCK-related encephalopathy. Light blue fill in family B indicates individuals affected by a hematologic
phenotype without neurodevelopmental features; neither is homozygous for p.Lys455*. WES was performed on individuals marked
with asterisks.
(E–J) Images show the similar facial features and hypotonia in individual A-II-1 at 25 months (E) and 13 years (F), individual B-IV-4 at
17 months (G) and 4 years, 3 months (H), individual B-IV-6 at 18 months (I), individual C-II-1 at 21 months (J), and individual D-II-1 at
14 years. See Table 1 for detailed clinical information on each affected individual and Figure 2 and Table S3 for imaging information.in family A; Figure 1, Table 1, and Table S2) was referred to
one of us with the tentative diagnosis of Joubert syndrome
(MIM: PS213300) with atypical features. Twenty-seven
genes previously implicated in Joubert syndrome were
screened,10 but no mutations predicted to be pathogenic
were found. Upon re-evaluation, the clinical and MRI fea-
tures (i.e., early respiratory failure, epilepsy, developmental
regression, dysmorphic features, and absence of classic im-
aging features) were inconsistent with the diagnosis of Jou-
bert syndrome, which suggested that this person instead
had a condition involving a hindbrain malformation
that had not been previously delineated. Subsequently,
WES was performed by the University of Washington Cen-
ter forMendelian Genomics (UW-CMG) as described previ-
ously.11 Single-nucleotide variants (SNVs) were annotated
with the SeattleSeq137 Annotation Server. SNVs catego-
rized as intergenic, coding synonymous, in the UTR, near
a gene, or intronic were excluded. Variants flagged as lowThe Amquality or potential false positives (quality score % 50,
long homopolymer run > 4, low quality by depth < 5, or
within a cluster of SNPs), as well as those with amean alter-
native allele frequency > 0.005 in the NHLBI Exome
Sequencing Project (ESP) Exome Variant Server (ESP6500)
or in an internal WES database of ~700 exomes, were
also excluded. Allowing for recessive and X-linked inheri-
tance, this filtering left 30 candidate genes (Table S1);
however, 27 genes could be excluded because they con-
tained one variant present as homozygous in the Exome
Aggregation Consortium (ExAC) Browser or with a CADD
score % 15.12 Only one gene, TBCK, harbored a biallelic
truncating variant (chr4: 107,183,260 G>A [UCSC
Genome Browser build hg19], c.376C>T [p.Arg126*]
[GenBank: NM_001163435.2]), so TBCK was considered
the best candidate. No other individuals with TBCKmuta-
tions were known at the time, so this candidate gene was
internally archived in 2013 and later in Geno2MP,
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recently released web-based tool that was developed by the
UW-CMG and that links phenotypic descriptions to rare-
variant genotypes in ~3,800 exomes from families affected
by Mendelian conditions.
In late 2014, two affected cousins in a second family
were ascertained on the basis of an apparently novel
neurodegenerative phenotype including cerebellar hypo-
plasia (family B; Figure 1, Table 1, and Table S2). Samples
from the extended family underwent high-density geno-
typing and WES by the UW-CMG as described previ-
ously.11 Linkage analysis conducted under a recessive
model, assuming a causal allele frequency of 0.0001
and full penetrance (f ¼ 0,0,1.0), yielded two peaks
(chr4: 88,837,705–109,066,366 and chr7: 81,735,015–
112,087,033 [hg19]) with a maximum parametric LOD
score of 2.48. WES data were annotated with the
SeattleSeq138 Annotation Server. As with the analysis for
family A, variants unlikely to impact protein-coding
sequence, variants flagged by the Genome Analysis Toolkit
(GATK) as lowquality, andvariantswithanalternativeallele
frequency> 0.002 in any population in ESP6500, 1000 Ge-
nomes (phase 3 release), or the ExAC Browser (v.1.0) were
excluded. Copy-number-variant calls were generated from
exome data with CoNIFER.14 After the linkage and exome
data were overlapped, only three genes, VPS50 (MIM:
616465; chr7: 92,953,034 G>A [hg19], c.1877G>A
[p.Arg626Gln] [GenBank: NM_001257998.1]), LRCH4
(chr7: 100,173,865 C>T [hg19], c.1634G>A [p.Arg545His]
[GenBank: NM_002319.3], rs370008127), and TBCK
(chr4: 107,156,512 T>A [hg19], c.1363A>T [p.Lys455*]
[GenBank: NM_001163435.2], rs376699648), remained as
candidates. All three geneswere submitted toGeneMatcher
andGeno2MP. Nomatches were found forVPS50 or LRCH4
in either database, but Geno2MP yielded a single individual
(individual A-II-1; Figure 1 and Table 1) who had cerebellar
malformation and was homozygous for a nonsense variant
in TBCK. Sharing of the same candidate gene and an over-
lappingphenotype suggested that theputative loss-of-func-
tion mutations in TBCK are causal.
In parallel, a third family was ascertained on the basis
of profound developmental disability associated with
brain atrophy before 2 years of age in a son and death of
a 12-month-old daughter exhibiting similar features
(family C; Figure 1, Table 1, and Table S2). WES was per-
formed on a sample from the affected son (individual
C-II-1). Variants were called with an in-house pipe-
line15–17 and filtered against public and in-house data-
bases; only clinically associated variants and variants
with a alternative allele frequency < 0.001 (dbSNP142),
< 0.002 (ExAC), or < 0.01 (in-house database with ~500
exomes) or an unknown alternative allele frequency were
retained. The SnpEff toolbox (v.4.1) was used for predicting
the impact of variants, which were filtered until only func-
tionally relevant variants (i.e., missense variants, nonsense
variants, coding indel variants, and intronic variants
located from5 toþ5 with respect to an exon-intron junc-
tion) remained. Functional annotation of variants was774 The American Journal of Human Genetics 98, 772–781, April 7, 2performed with SnpEff v.4.1 and dbNSFP v.2.8. Parental
first-cousin consanguinity and the death of a female sib-
ling with similar clinical features (i.e., suggestive facies, se-
vere developmental delay, generalized hypotonia, and
congenital heart malformation) strongly suggested auto-
somal-recessive inheritance, and on the basis of the
hypothesis of homozygosity by descent, 16 candidate
genes were identified. These candidates were stratified
through a mixed filtering and prioritization strategy de-
signed to retain genes with variants predicted to be
damaging (CADD_phred > 15) and rank them on the basis
of their biological relevance to the developmental pro-
cesses altered in the disorder (GeneDistiller) (see Table
S1).18 Among the eight retained genes, TBCK (chr4:
107,154,202 C>T [hg19], c.1532G>A [p.Arg511His]
[GenBank: NM_001163435.2]) received the highest score
from GeneDistiller and was considered the best candidate.
At this point, an inquiry was made about whether TBCK
was a candidate gene for any phenotypes being studied
at the UW-CMG.
Finally, another individual of Puerto Rican descent and
with severe hypotonia, chronic respiratory insufficiency
requiring nighttime BiPAP (bilevel positive airway pres-
sure), brain atrophy, and similar facial features (individual
D-II-1; Figures 1 and 2) was ascertained in parallel. Clinical
exome sequencing identified the same homozygous
c.376C>T (p.Arg126*) variant present in individual
A-II-1, supporting the existence of a founder mutation in
the Puerto Rican population. The phenotypic features in
individual D-II-1 were quite similar to those of the other
affected individuals (Table 1 and Tables S2 and S3).
The variants in each family were either rare or not pre-
sent in reference population databases. Specifically, the
maximum alternative allele frequency in any population
from ESP6500, 1000 Genomes phase 3, or ExAC Browser
v.0.3 was 0.5208% for p.Arg126* (families A and D) and
0.0107% for p.Lys455* (family B) in ExAC Latinos, whereas
p.Arg511His (family C) was not present in any database.
Each variant had a high CADD score:12 37.0 for
p.Arg126*, 42.0 for p.Lys455*, and 35.0 for p.Arg511His.
All affected individuals displayed profound develop-
mental disability (because of which they made little prog-
ress beyond infancy) and a relatively homogeneous
phenotype (Table 1 and Figure 1). Additionally, individuals
A-II-1, B-IV-4, and B-IV-6 exhibited developmental regres-
sion (loss of visual fixation and following). All four individ-
uals also required gastrostomy-tube feedings and had
decreased respiratory drive, and the three older children
required tracheostomies for chronic mechanical ventila-
tion. Individuals A-II-1, B-IV-4, and B-IV-6 also developed
focal seizures between 2 and 6 years of age, and individual
C-II-1 had an abnormal electroencephalogram before 2
years of age without clinical seizures. Individuals A-II-1,
B-IV-4, and C-II-1 had decreased to absent reflexes, whereas
individual B-IV-6 developed hyperreflexia. Shared facial
features included bitemporal narrowing, arched eyebrows,
deep-set eyes, a high nasal bridge, anteverted nares, and an016
Table 1. Clinical Features of Individuals with TBCK-Related Encephalopathy
Affected Individuals
A-II-1 B-IV-4 B-IV-6 C-II-1 D-II-1
Mutation c.376C>T (p.Arg126*) c.1363A>T (p.Lys455*) c.1363A>T (p.Lys455*) c.1532G>A (p.Arg511His) c.376C>T (p.Arg126*)
Demographics
Age 14 years 4 years 10 years (deceased) 24 months 14 years
Sex male female female male male
Ethnicity Puerto Rican Lebanese Lebanese Egyptian Puerto Rican
Consanguinity no first cousin first cousin first cousin no
Family history mother and sister with cleft lip and palate,
sister with arrhythmia
two brothers with hematologic
disorder
two male cousins with
hematologic disorder
similarly affected sister
(deceased)
negative
Physical and Neurological Features
Birth weight 4.15 kg 4.2 kg 3.78 kg unknown 2.72 kg
Birth OFC 38.5 cm (75th percentile) 37 cm (90th percentile) 35 cm (50th percentile) unknown unknown
Current OFC 55 cm (57th percentile) 53.5 cm (75th percentile) 53 cm (50th percentile) 49 cm (50th–70th percentile) 53 cm (19th percentile)
Developmental disability profound profound profound profound profound
Developmental regression yes yes yes no yes
Reflexes decreased or absent decreased or absent proximally increased, distally
areflexic
decreased or absent decreased or absent
Severe hypotonia yes yes yes yes yes
Seizures focal, refractory focal, controlled on AED tonic seizures, controlled on AED no (abnormal EEG) mixed focal and generalized,
controlled on AED
Age of onset of seizures 2.5 years 25 months 6 years NA 11 months (with fever),
15 months (afebrile)
Eyes and vision cataracts, ptosis, cortical visual impairment cortical visual impairment visual impairment bilateral optical atrophy,
severe esotropia
cortical visual impairment,
normal ERG
Hearing normal normal normal normal normal
Respiration chronic respiratory insufficiency,
tracheostomy at 4 months
chronic respiratory insufficiency,
tracheostomy at 2 years
chronic respiratory insufficiency,
tracheostomy at 4 years
hypoventilation chronic respiratory
insufficiency, BiPAP at night,
O2 as necessary via NC
Feeding G-tube G-tube G-tube G-tube G-tube
Other features right preauricular pit, gingival hyperplasia,
macroglossia, neurogenic bladder
(vesicostomy), subdural hematoma (unclear
etiology), metabolic stroke, osteoporosis
(three femur fractures), hypertriglyceridemia
mild virilization of external
genitalia as a neonate
(subsequently normalized),
turricephaly, osteoporosis
muscle fasciculations, increased
muscle bulk, elevated creatine
kinase (800 IU/L) during viral
infection (not repeated),
osteoporosis
right-sided aortic arch,
11 ribs, turricephaly,
hypertrichosis
hypertriglyceridemia,
tongue fasciculations,
intermittent hyponatremia,
osteoporosis
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776 The American Journal of Human Genetics 98, 772–781, April 7, 2exaggerated ‘‘Cupid’s bow’’ of the upper lip (Figures 1D–
1H). Individuals A-II-1 and B-IV-6 developed osteoporosis,
which could be either a non-specific effect of chronic, se-
vere disability or a more specific feature of TBCK-related
disease. At 3 years of age, individual A-II-1 had an acute
neurological decompensation with restricted diffusion
of the right parieto-occipital cortex, indicative of a meta-
bolic stroke, from which he recovered to his baseline
neurological status. In all four individuals, brain imaging
revealed increased ventricular and extra-axial spaces and
diffusely decreased white-matter volume, and atrophy
was confirmed by serial MRI in individuals A-II-1 and
B-IV-4 (Figure 2 and Table S3). Despite the loss of brain
volume, microcephaly was not observed. In addition, all
individuals showed dysgenesis of the corpus callosum
(thinning, partial agenesis, or both), increased T2-
weighted FLAIR signal in the periventricular white matter,
and cerebellar vermis hypoplasia.
TBCK encodes a protein with a TBC (Tre-2, Bub2, and
Cdc16) domain flanked by an N-terminal kinase-like
domain and a rhodanese homology domain at the C termi-
nus, but its function has not been extensively character-
ized. Because of a lack of key catalytic residues, the kinase
domain is presumably inactive.19 Multiple TBCK mRNAs
have been reported, and two major isoforms differ in the
presence or absence of the portion that encodes the N-ter-
minal kinase-like domain (Figure 3A).20 For characterizing
the impact of the truncating mutations, the amount of
TBCK was evaluated by western blot with the use of skin
fibroblasts obtained from individual A-II-1, who is homo-
zygous for c.376C>T (p.Arg126*) (Figure 3B). As expected,
twomajor bands at ~101 and 71 kDa, representing the long
(full-length) protein and the shorter isoform without
the N-terminal kinase-like domain,20 respectively, were
observed in two control fibroblast lines, and the full-length
isoform was more abundant. In contrast, the full-length
protein was nearly absent in the fibroblasts from individ-
ual A-II-1, and the 71 kDa isoform was also reduced.
Although the transcript for the 71 kDa isoform is not
directly affected by the mutation, the reduced protein
amount indicates that the mutation perturbs the levels of
both major TBCK isoforms in fibroblasts.
The c.1532G>A (p.Arg511His) mutation in individual
C-II-1 is predicted to alter a highly conserved arginine
residue located in the TBC1 domain (Figure 3C). This struc-
tural unit of approximately 200 amino acids is character-
istic of most GAPs that regulate the Rab family of small
GTPases.21,22 TBC domains negatively control Rab func-
tion by promoting GTP hydrolysis via stabilization of the
transition state of the reaction. Specifically, the TBC
domain interacts with the substrate and catalyzes the reac-
tion by using a so-called ‘‘dual-finger’’ mechanism, in
which a key Arg residue projects into the Rab active
site.23–25 Because no crystallographic structure of TBCK
was available, a homology model of the TBC1 domain of
TBCK (residues 467–648) in complex with a Rab protein
was constructed for exploring the structural impact of016
Figure 2. Brain-Imaging Features in Individuals with TBCK-Related Encephalopathy
(A–D) Axial T2-weighted (A and C) and sagittal T1-weighted images (B and D) show progressive loss of gray- and white-matter volume
(most severe in the frontal lobes), demonstrated by increasing ventriculomegaly and extra-axial spaces (cortical and cerebellar) in indi-
vidual A-II-1 between 22 days of age (A and B) and 29 months of age (C and D). Also present are swelling of the right parieto-occipital
lobe, presumably due to a metabolic stroke (bracket in C), a diffusely thin corpus callosumwith absent rostrum (arrowheads in B and D),
and mild cerebellar vermis hypoplasia with a relatively spared brainstem.
(E and F) Axial T2-weighted (E) and sagittal T1-weighted (F) images show ventriculomegaly, prominent extra-axial spaces, a diffusely thin
but complete corpus callosum, and mild cerebellar vermis hypoplasia in individual B-IV-4 at 18 months of age. Right plagiocephaly is
also present.
(G and H) Axial T2-weighted (G) and sagittal T1-weighted (H) images show marked ventriculomegaly, prominent extra-axial spaces, a
diffusely thin but complete corpus callosum, and mild cerebellar vermis hypoplasia in individual B-IV-6 at 6 years of age. Synechiae
are also present in the right frontal horn (asterisks in G).
(I and J) Axial T1-weighted (I) and sagittal T1-weighted (J) images show ventriculomegaly, prominent extra-axial spaces, a diffusely thin
corpus callosumwith an absent rostrum and anterior body (arrowhead in J), andmild cerebellar vermis hypoplasia in individual C-II-1 at
21 months of age.
(K and L) Axial T2-weighted (K) and sagittal T1-weighted (L) images show mild ventriculomegaly, prominent extra-axial spaces, a
diffusely thin corpus callosum, mild cerebellar vermis hypoplasia with a relatively preserved brainstem, and a thick frontal bone (arrow
in K) in individual D-II-1 at 14 years of age.the disease-causing amino acid substitution. This model
was generated with DeepView and the SwissModel
server26 on the basis of the crystallographic structure of
the Gyp1 TBC domain (36% sequence identity with the
TBCK TBC domain) complexed with Rab33 bound to
GDP and AlF3 (PDB: 2G77).23 TBCK was originally incor-
rectly classified as an unconventional TBC protein lacking
the ‘‘arginine finger’’;21 however, our modeling data sup-
port more recent bioinformatics analyses21 indicating
that Arg511 does in fact represent an arginine finger essen-
tial for GAP function. The p.Arg511His substitution wasThe Amintroduced in silico with UCSF Chimera,27 and even
though the Arg-to-His substitution introduces a side chain
that could maintain the overall positive charge under
appropriate conditions,28 the introduced residue is signifi-
cantly bulkier and shorter than Arg and is unable to project
into the GTPase active site. In the model, the minimum
distance between Arg511 and the GDP phosphate is 3 A˚,
whereas this distance increases to 7 A˚ in the mutant. These
considerations strongly point to impaired GAP activity as
the predicted mechanism of disease associated with the
p.Arg511His substitution.erican Journal of Human Genetics 98, 772–781, April 7, 2016 777
Figure 3. Biochemical and Structural Characterization of TBCK Mutations
(A) TBCK encodes two isoforms containing a TBC1 domain (TBC) flanked by a rhodanese domain (RHOD) at the C terminus. The long
isoform also contains a pseudokinase domain (STYKc) at the N terminus. The location of the identified variants is reported.
(B)Western blot shows that TBCK amounts were dramatically lower in a cell line from individual A-II-1 than in two control cell lines. The
TBCK monoclonal antibody (1/250, Sigma HPA039951) recognizes a C-terminal fragment of the protein (depicted as a red line in A).
After stripping, b-actin (1/5,000, Sigma A5441) was used as a loading control. The predicted sizes of the TBCK long and short isoforms
are 101 and 71 kDa, respectively.
(C) Conservation of the catalytic arginine ‘‘finger’’ (Arg511 in TBCK) in TBCK orthologs.
(D) Homology model of the TBCK TBC1 domain complexed with the Rab33 GTPase. In the overall structure of the complex (left), both
proteins are shown in a surface representation; Rab is colored pink, GDP is gray, the TBC1 domain is light blue, and Arg511 is dark blue.
In the enlarged view of the active site of the GTPase (right), GDP is reported in gray sticks, and the phosphates are colored orange. AlF3,
which in the crystal structure mimics the transition state for GTP hydrolysis, is shown in yellow, and the Mg atom is shown as a purple
sphere. The TBC1 domain is reported in ribbon representation, and the side chains of key residues are shown as sticks. The two catalytic
‘‘fingers’’ Arg511 (blue) and Gln546 (green) are shown together with the disease-associated His511, shown in semi-transparent red.TBCK was recently documented to play a role in the con-
trol of cell proliferation, cell size, and actin-cytoskeleton
dynamics.19,20 Althought the lack of several residues with
critical function in mediating the activity of the kinase
domain supports the view that TBCK is catalytically inac-
tive,29,30 the conservation of the key catalytic residues of
the TBC1 domain, as well as the identification of a dis-
ease-causing mutation specifically targeting one of the
two key residues of this domain (Arg511), points to the
relevance of Rab-GAP activity for TBCK function, even
though its physiological targets have not been identi-
fied.19 Indeed, the ‘‘Arg finger’’ is conserved in virtually
all TBC domains with GAP activity,21,22,25 and it is largely
accepted that unconventional TBC domains lacking this
residue do not stimulate GTP hydrolysis in Rab proteins
but rather have different functions.21,22,25 Of note, one
of the human unconventional TBC proteins (TBC1D26)
and its Chlamydomonas reinhardtii ortholog have a histi-
dine residue in place of the ‘‘catalytic’’ arginine, and no
GAP activity was detected in the algal protein.31 Mutation
of the ‘‘catalytic’’ Arg in TBC-domain-containing proteins
is commonly used as a tool for investigating their function
and identifying their substrate Rabs,22,32–35 given that sub-
stitution of this amino acid greatly reduces the catalytic
efficiency of these GAPs.14778 The American Journal of Human Genetics 98, 772–781, April 7, 2TBCK’s role in controlling cell proliferation and growth
and actin-cytoskeleton organization has been reported to
be mediated by modulation of the mTOR (mammalian
target of rapamycin) signaling network and transcriptional
regulation of components of the mTOR complex.19 The
mTOR pathway is a growth-regulating network, which in
an activated state promotes angiogenesis, cell growth,
and cell proliferation. A number of developmental brain
disorders, collectively termed ‘‘TORopathies,’’ have been
shown to result from dysregulated mTOR signaling.36,37
These disorders are characterized by disorganized cortical
lamination, seizures, and cytomegaly.38 Tuberous sclerosis
complex (TSC [MIM: PS191100]) is caused by heterozygous
loss-of-function mutations in TSC1 (MIM: 605284) or
TSC2 (MIM: 191092), encoding proteins that negatively
regulate the mTOR pathway. Similarly, in addition to play-
ing a well-documented role in cancer, germline or postzy-
gotic activating de novo mutations in genes encoding
components of the PI3K-AKT3-mTOR pathway cause the
overlapping hemimegalencephaly phenotypes megalence-
phaly-capillary malformation-polymicrogyria syndrome
(MIM: 602501; usually caused by somatic mutations in
PIK3CA [MIM: 171834]) and megalencephaly-poly-
microgyria-polydactyly-hydrocephalus syndrome (MIM:
PS603387; usually caused by germline mutations in016
PIK3R2 [MIM: 603157], CCND2 [MIM: 123833], and AKT3
[MIM: 611223]). More recently, germline gain-of-function
mutations inMTOR (MIM: 601231) have been described in
two families affected by features overlapping the megalen-
cephaly and RASopathy spectra of disorders.36,39 These
TORopathies are all caused by activation of the mTOR
pathway and are generally characterized by brain over-
growth at a global (hemimegalencephaly spectrum) or
focal (TSC) level. In contrast, loss of TBCK function is asso-
ciated with loss of brain volume. In combination with
available biochemical and functional data supporting a
positive modulatory role for TBCK on mTOR signaling,19
our findings suggest that loss of TBCK function affects
this signaling network in a way that opposes what is
observed in other mTOR-related disorders and, impor-
tantly, that over-inhibition of the mTOR pathway might
lead to this distinct and severe phenotype. Some of the
affected individuals were found to have moderate mito-
chondrial dysfunction that did not meetWalker diagnostic
criteria40 for a primary respiratory chain disorder and was
not associated with increased brain lactate in the three in-
dividuals evaluated by magnetic resonance spectroscopy
(Table S3). Given that the mTOR pathway is known to
positively affect mitochondrial biogenesis41 and nega-
tively regulate autophagy and mitophagy (reviewed in
Bockaert and Marin42) and that several individuals showed
decreased mitochondrial enzyme levels, we hypothesize
that the progression of the disease might be due in part
to decreased mitochondrial biogenesis and/or increased
mitophagy.
In summary, we have established that biallelicmutations
in TBCK cause a severe neurodevelopmental disorder
whose major features include profound developmental
delay or cognitive deficit, brain atrophy without micro-
cephaly, dysgenesis of the corpus callosum, abnormal
white-matter signal, cerebellar vermis hypoplasia, seizures,
diminished respiratory function, and distinctive facies.
Further strengthening this view is the recent report of
a similar individual exhibiting severe developmental
disability, poor feeding, abnormal eye movements, epi-
lepsy, facial dysmorphism, severe hypotonia, and diffuse
brain atrophy associated with a homozygous canonical
splice-site mutation (c.1897þ1G>A [GenBank: NM_
001163435.1]) in TBCK.43 Structural and molecular-
modeling analyses predict a key role for the substituted
residue in mediating the Rab-GAP activity of the protein,
suggesting that loss of TBCK GAP function is sufficient to
cause disease. Of note, many encephalopathies are caused
by de novo dominant mutations and therefore have low
risk of recurrence, so distinguishing TBCK-related enceph-
alopathy is essential for accurate recurrence-risk coun-
seling and reproductive planning. Recognition of this
disorder will also make it possible to delineate the natural
history of TBCK-related disease and provide more precise
prognostic information essential for guiding decisions
about invasive treatments such as tracheostomy and gas-
trostomy in neonates and young children.The AmMore than 3 years passed between the identification of
TBCK as the strongest candidate gene in family A and
the identification of TBCK mutations in families B, C,
and D. Importantly, even though two families were
sequenced through the same center (UW-CMG), their
shared phenotype was not initially recognized, in part
because the clinicians rightfully focused on different as-
pects of each affected individual’s condition. The identifi-
cation of a shared candidate gene through a search of
Geno2MP prompted comparison of the clinical findings
and led to delineation of an overlapping phenotype. It is
anticipated that matchmaking platforms in development,
such as Matchmaker Exchange,44 will help to speed up
this process, but only if investigators and clinicians
worldwide all participate in such data-sharing efforts. His-
torically, ascertaining persons with a highly similar pheno-
type and then conducting subsequent gene discovery
within that group has been a successful method for under-
standing new Mendelian phenotypes; however, this
approach requires the Mendelian phenotype to be com-
mon enough that a single investigator could be expected
to encounter multiple affected individuals. The small
number of individuals with biallelic mutations in TBCK
identified thus far, and the international assemblage of in-
vestigators who identified these individuals, underscores
the fact that many, if not most, Mendelian phenotypes
now being studied will be more rapidly and successfully
tackled by widespread sharing of phenotypes, genotypes,
and candidate genes.13,44,45Supplemental Data
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